PROGRAM CHAIRS
Shubham Pant, MD, MBBS
Department of Gastrointestinal Medical Oncology and
Department of Investigational Cancer Therapeutics
University of Texas MD Anderson Cancer Center
Houston, TX
Mariela Blum Murphy, MD
Associate Professor
Department of Gastrointestinal Medical Oncology
University of Texas MD Anderson Cancer Center
Houston, TX
PROGRAM OVERVIEW
This enduring activity aims to enhance healthcare providers’ ability to recognize actionable genetic mutations serving as biomarkers for potential targeted therapies in patients with advanced gastric and gastroesophageal (GC/GEJ) cancers. This program features the latest clinical trial findings on new and emerging agents for first- and second-line therapies for advanced GC/GEJ cancers, along with strategies for managing and addressing potential adverse events associated with these treatments.
TARGET AUDIENCE
This activity is designed to meet the educational needs of community and academic medical oncologists, NPs/PAs, nurses, pathologists, and other HCPs involved in the management of patients with gastric and gastroesophageal junction cancers.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Review the biomarkers and genetic aberrations that are currently actionable or may become actionable in the near future for patients with advanced GC/GEJ cancers
- Apply the latest clinical trial data of new and emerging agents for the optimal selection and sequencing of first- and second-line therapies for advanced GC/GEJ cancers
- Describe the presentation and management of potential AEs associated with new and emerging agents for the treatment of advanced GC/GEJ
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Shubham Pant, MD, MBBS | Discloses that he has received consulting fees for Zymeworks, Ipsen, Novartis, Janssen, AskGene Pharma, BPGBio, Jazz, AstraZeneca, Boehringer Ingelheim, USWorldmeds, Nihon Medi-Physics Co, Ltd, and Alligator Bioscience He has conducted contracted research for Mirati Therapeutics, Lilly, Xencor, Novartis, Bristol Myers Squibb, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim and NGM Pharmaceuticals. |
| Mariela Blum Murphy, MD | Discloses that she is on the advisory board for Eisai and AstraZeneca |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Stephanie Mutch, RD, MSN, has nothing to disclose.
- Sireesha Murala, Medical Director for Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager for Med Learning Group, has nothing to disclose.
- Jessica Feygin-Samuels, Associate Program Manager for Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
- Russie Allen, Accreditation and Outcomes Manager of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: August 02, 2024
EXPIRATION DATE: August 02, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
